For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

IGF-1 LR3

Also known as: Long R3 IGF-1

IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog with a 13-residue N-terminal extension (MFPAMPLSSLFVN) and an Arg-3 substitution. These modifications reduce binding to IGF binding proteins (IGFBPs), extending effective half-life and increasing tissue bioavailability relative to native IGF-1. It is a research/cell-culture reagent and is NOT FDA-approved for any human use. Do not confuse with mecasermin (Increlex), which is recombinant human IGF-1 and IS FDA-approved for severe primary IGF-1 deficiency.

Where to buy · live market data

Who's worth your money for IGF-1 LR3

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 21 scored sellers

$64.99/mg

$64.99 · 1mg

no COAs yet
Buy Code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$0.00/mg

— · 1mg · 99.3% purity

Most tested

7 independent COAs on file

$65.00/mg

$65.00 · 1mg · 99.8% purity

Average price

$70.21/mg

Sellers

46

45-day trend

-18.2%

28 of 46 sellers have a current price· 3 stale hidden· 4 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch IGF-1 LR3

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About IGF-1 LR3

CAS

143045-27-6

Molecular formula

C400H619N111O115S9

Sequence

MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA

Typical dose range

20-100 mcg/day subcutaneous or intramuscular injection (research use; commonly 20-50 mcg/day in published protocols)

Half-life

~20-30 hours

Independent evidence

COAs for IGF-1 LR3

68 third-party tests across 25 vendors. Each card links to the full report.

All 68 COAs for IGF-1 LR3 →
Measured purity 95.0%–100.0% across 47 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.73 %
Jul 2026
ILS Labs Strong

For

IGF-1 LR3

by Voltera Sciences· batch IGF1-07082026

Aggregated · 3rd-party listing
99.14 %
Jun 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Peptide Plugs· batch 140-01-DK

Aggregated · 3rd-party listing
99.77 %
Jun 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Nova Peptides· batch NV-P-ZE8J

✓ Vendor-published
99.66 %
May 2026
Kovera Labs

For

IGF-1 LR3

by Ion Peptide· batch IGF1-05042026

COA on file
Aggregated · 3rd-party listing
99.16 %
May 2026
ILS Labs Strong

For

IGF-1 LR3

by Ion Peptide· batch IGF1-052026

✓ Vendor-published
99.16 %
May 2026
ILS Laboratories

For

IGF-1 LR3

by Ion Peptide· batch IGF1-052026

COA on file
Aggregated · 3rd-party listing
99.22 %
May 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Peptide Supply Co.· batch IG105192026

Aggregated · 3rd-party listing
99.95 %
Apr 2026
Biogenica Labs · HPLC

For

IGF-1 LR3

by Amino Club· batch IGF0001

Aggregated · 3rd-party listing
97.05 %
Apr 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Nova Peptides· batch NV-P-XRXV

Aggregated · 3rd-party listing
99.60 %
Mar 2026
Analytical Formulations, Inc.

For

IGF-1 LR3

by Ion Peptide· batch IGF1-03102026

Aggregated · 3rd-party listing
99.16 %
Mar 2026
Freedom Diagnostics Moderate · HPLC

For

IGF-1 LR3

by Peptide Supply Co.· batch GLR31031026

Aggregated · 3rd-party listing
99.53 %
Mar 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Real Peptides

Aggregated · 3rd-party listing
99.10 %
Mar 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Nova Peptides· batch NV-P-0FU2

✓ Vendor-published
98.89 %
Feb 2026
Vanguard Laboratory Strong

For

IGF-1 LR3

by Mile High Compounds· batch IGF-001-MH-02

COA on file
Aggregated · 3rd-party listing
98.87 %
Feb 2026
Vanguard Laboratory Strong · HPLC

For

IGF-1 LR3

by Mile High Compounds· batch IGF-001-MH-02

Aggregated · 3rd-party listing
99.80 %
Feb 2026
Vanguard Laboratory Strong

For

IGF-1 LR3

by Peptide Crafters· batch PC-J2-IGF1

✓ Vendor-published
99.03 %
Feb 2026
Vanguard Laboratory Strong

For

IGF1 LR3

by Licensed Peptides· batch IGF1LR3-01

COA on file
Aggregated · 3rd-party listing
99.80 %
Jan 2026
Bioviridian Moderate

For

IGF-LR3

by Ion Peptide· batch IGFL-010226

Aggregated · 3rd-party listing
99.06 %
Jan 2026
Janoshik Analytical Limited · HPLC

For

IGF-1 LR3

by Skye Peptides· batch IGF25-1-003

Aggregated · 3rd-party listing
95.28 %
Dec 2025
Chromate Moderate

For

IGF-1 LR3

by Orbitrex Peptides

Aggregated · 3rd-party listing
99.08 %
Dec 2025
Freedom Diagnostics Moderate · HPLC

For

IGF-LR3

by Simple Peptide· batch IGFR12172025-J

✓ Vendor-published
95.04 %
Nov 2025
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Ion Peptide· batch IL1-1025

COA on file
Aggregated · 3rd-party listing
96.27 %
Nov 2025
Janoshik Analytical Limited · HPLC

For

IGF-1 LR3

by ZLZ peptides· batch cmojgromn00539grxzzwqeri4

Aggregated · 3rd-party listing
95.04 %
Nov 2025
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Ion Peptide· batch IL-L-1025

Research depth

12 citations indexed for IGF-1 LR3

All research on IGF-1 LR3 →

Study · 2026

IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering

Tissue engineering using the self-assembly approach represents a promising technology. However, age-related reductions in extracellular matrix deposition by stromal cells limit the mechanical robustness of reconstructed tissues what can be critical for midurethral sling reconstruction.

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

Study · 2026

Intact Proteoform Analysis by Capillary Electrophoresis-Mass Spectrometry. Are We There Yet?

Mass spectrometry (MS)-based top-down proteomics (TDP) has emerged as a powerful tool for characterizing proteoforms to advance both fundamental and translational research. TDP requires high-efficiency liquid-phase separation, high-resolution MS, and tandem MS.

review · 2026

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.

Study · 2026

Self-Organized Vascularized Human Liver Spheroids: Serum-Free Culture Conditions and Use as Tissue Building Blocks

Engineering vascularized human liver tissue for in vitro and in vivo applications remains a major challenge.

Study · 2026

Growth factor thermostability dataset derived from experimental and computational approaches to accelerate cultured meat development

This project compiled experimentally measured and computationally predicted thermostability data for growth factors (GFs) commonly used in cultured meat and seafood (CM) production.